share_log

Body and Mind Narrows Loss By 30% YoY In Q3, Doubles Down On Streamlining Operations

Body and Mind Narrows Loss By 30% YoY In Q3, Doubles Down On Streamlining Operations

身心在第三季度的虧損減少了30%,並加倍精簡經營。
Benzinga ·  06/22 03:08

Body and Mind Inc. (CSE:BAMM) (OTCQB:BMMJ) announced on Friday its financial results for the third quarter of fiscal year 2024 ended April 30, 2024.

Body and Mind公司(CSE: BAMM)(OTCQB: BMMJ)宣佈其2024財年第三季度截至2024年4月30日的財務業績。

Michael Mills, the company's CEO, said in a press release that BaM is working on streamlining its operations. "We continue to execute our strategy of reducing our footprint and focusing on developing our most valuable assets."

公司首席執行官邁克爾·米爾斯在新聞稿中表示,BaM正在簡化其運營。"我們繼續執行減少佔地面積、專注於開發我們最有價值的資產的戰略。"

In Illinois, the company's Markham-based dispensary shows signs of growth, while the building project in the Lynwood store is in its final stages, the company said.

該公司位於伊利諾伊州馬克姆的藥店的發展表現良好,而該公司林伍德商店的建築項目處於最後階段。

"We're pleased that our Lynwood, Illinois location has recently received approval to connect the completed building to services and commence required roadwork," Mills continued. "We look forward to completing construction for this operation shortly.

"我們很高興我們伊利諾伊州林伍德市的位置最近已獲得批准,將完成建樓並開始所需的道路工程,"米爾斯繼續說。"我們期待不久即可完成此運營的建設。

BaM also received the New Jersey Annual license for BaM Body and Mind Dispensary NJ, Inc. The dispensary will be 4,000 square feet. The retail location in Lawrenceville is in a jurisdiction that has approved only two dispensaries.

BaM也獲得了BaM Body and Mind Dispensary NJ,Inc.的新澤西州年度許可證。 該診所的面積爲4,000平方英尺。 勞倫斯維爾的零售位置是一個只批准了兩個診所的管轄區。

"We believe the Illinois and New Jersey markets remain underserved and our strong locations and capabilities will support high-returning operations for the Company and shareholders," Mills added.

"我們認爲伊利諾伊州和新澤西州市場仍然供不應求,並且我們強大的位置和能力將支持公司股東的高回報運營。"米爾斯補充道。

To learn more about cannabis stocks, come join us at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.

要了解有關大麻股票的更多信息,請於今年10月8日至9日來參加第19屆Benzinga大麻資本會議。通過以下鏈接獲取門票,避免價格上漲。

Q3 2024 Financial Highlights

2024年Q3財務亮點:

  • Revenue totaled $4.41 million, compared to $4.17 million in the prior year's period.
  • Gross profit was $1.96 million, up from $1.93 million in the third quarter of fiscal 2024.
  • Net operating loss was $1.34 million, representing an increase from $1.28 million in the corresponding quarter of last year.
  • Net loss totaled $2.54 million, representing an improvement from $3.61 million net loss in the prior year's period.
  • As of April 30, 2024, the company had $16.2 million in total assets and $28.1 million in total liabilities, compared to $21.2 million and $30.5 million, respectively, as of July 31, 2023.
  • 營收總額爲441萬美元,而去年同期爲417萬美元。
  • 毛利潤爲196萬美元,而2024財年第三季度爲193萬美元。
  • 經營虧損爲134萬美元,而去年同期爲128萬美元。
  • 淨虧損總額爲254萬美元,而去年同期的淨虧損爲361萬美元。
  • 截至2024年4月30日,該公司總資產爲1620萬美元,總負債爲2810萬美元,而截至2023年7月31日分別爲2,120萬美元和3,050萬美元。

Nine-Month Period Ended April 2023/Financial Highlights

截至2023年4月,九個月的時間已過去。財務亮點如下:

  • Revenue amounted to $13.4 million, up from $13.2 million in the same period of last year.
  • Gross profit was $6.05 million, representing an increase from $5.43 million in the prior year's period.
  • Net operating loss was $3.26 million, down from $3.83 million in the nine months ended April 30.
  • Net loss was $2.54 million, down from $9.3 million in the corresponding period of fiscal 2023.
  • 營收總額爲1340萬美元,而去年同期爲1320萬美元。
  • 毛利潤爲605萬美元,而去年同期爲543萬美元。
  • 經營虧損爲326萬美元,而2024年4月份的九個月則爲383萬美元。
  • 淨虧損總額爲254萬美元,而財政2023年相應時期爲930萬美元。

Related News

相關新聞資訊

  • Body and Mind's Q2 Revenue Flat YoY, Narrows Loss By 94%
  • Body And Mind's Q1 2024 Earnings: Ohio Sale Sparks Net Income Jump
  • Body and Mind Reports Revenue Dip In 2023 But CEO Is Optimistic About Future Growth
  • Body and Mind的Q2收入相比去年持平,虧損減少了94%
  • Body and Mind的2024年第一季度收益:俄亥俄州銷售引發淨收入激增
  • Body and Mind報告營業收入下降,但CEO對未來的創業板充滿樂觀

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論